News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Reinforcing commitment to ethical and sustainable growth
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The agreement complements other PPAs for Sandoz production sites globally
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Cenexi reports an EBITDA breakeven for the quarter
This will be Aster’s fifth hospital in Bengaluru
Subscribe To Our Newsletter & Stay Updated
